中山大便出血是什么病症(中山大便老出血是什么原因) (今日更新中)

WASHINGTON (AP) — Responding to an outcry from medical experts, Food and Drug Administration Commissioner Stephen Hahn on Tuesday apologized for overstating the life-saving benefits of treating COVID-19 patients with convalescent plasma.Scientists and medical experts have been pushing back against the claims about the treatment since President Donald Trump’s announcement on Sunday that the FDA had decided to issue emergency authorization for convalescent plasma, taken from patients who have recovered from the coronavirus and rich in antibodies.Trump hailed the decision as a historic breakthrough even though the treatment’s value has not been established.Hahn had echoed Trump in saying that 35 more people out of 100 would survive the coronavirus if they were treated with the plasma. That claim vastly overstated preliminary findings of Mayo Clinic observation. 878

WASHINGTON (AP) -- The Supreme Court has rejected the Trump administration's bid to throw out a California immigrant-sanctuary law that limits local police cooperation with federal immigration authorities.The justices' order Monday leaves in place lower court rulings that upheld the law.The administration said the 2017 state immigrant-sanctuary measure conflicts with federal immigration law and makes it harder to deport people who are in the country illegally.California Attorney General, Xavier Becerra, released a statement that said in part: "We’re protecting Californians’ right to decide how we do public safety in our state. The Trump Administration does not have the authority to commandeer state resources. We’re heartened by today’s Supreme Court decision."The San Diego County Sheriff's Department sent ABC 10News the following statement:"The Supreme Court decision not to hear a legal challenge to California's sanctuary law does not change or impact the operations of the San Diego County Sheriff's Department. Our agency is already in full compliance with SB54.We do not enforce immigration laws. We prioritize community relationships and want all residents to feel safe when reporting crimes or coming forward as a witness to criminal acts."The Sheriff's Department also sent the following documents related to the law:https://www.sdsheriff.net/documents/sb54.pdf [sdsheriff.net]https://www.sdsheriff.net/documents/SDSD%20Values%20Act%20Information%20Page.pdf [sdsheriff.net] 1502

Water update ** Nov 30, 6pm ** The city has issued a precautionary boil water alert. Read more: https://t.co/Qj9KyecGEW— City of Poway (@cityofpoway) December 1, 2019 180

WASHINGTON (AP) — Senate Majority Leader Mitch McConnell says the Senate will vote on a trimmed-down Republican coronavirus relief package, though it has a slim chance of passage in the face of Democrats’ insistence for more sweeping aid. He says the GOP will introduce a new targeted proposal, focused on healthcare, education, and economic issues. The Kentucky Republican released the approximately 0 billion measure as senators returned to Washington for an abbreviated pre-election session, as hopes are dimming for another coronavirus relief bill — or much else.McConnell is under pressure from GOP senators in tough reelection races. Those senators are eager to show constituents they are working to ease the pandemic’s strain on jobs and businesses. McConnell’s bill would provide 5 billion to help schools reopen, enact a shield against lawsuits for businesses and others that are powering ahead to reopen, create a scaled-back 0-per-week supplemental jobless benefit, and write off billion in earlier debt at the U.S. Postal Service. There’s billion for a coronavirus vaccine, billion for virus testing and billion to help child care providers reopen. There is additionally billion for farmers.McConnell acknowledged the package he will be putting forward “does not contain every idea our party likes.” And he said it was far less than what Democrats are seeking.But many Senate Republicans are resisting more spending. Talks between top Democrats and the Trump administration broke off last month. 1544

WASHINGTON, D.C. – Two different doses of a thyroid medication are being recalled because they're not potent enough.The Food and Drug Administration announced Thursday that Acella Pharmaceuticals is voluntarily recalling one lot of 15-milligram and one lot of 120-milligram NP Thyroid?, Thyroid Tablets.The products may have as low as 87% of the labeled amount of levothyroxine, which is used to treat hypothyroidism (an underactive thyroid), according to the FDA.The company’s risk statement says patients being treated for hypothyroidism who receive sub potent NP Thyroid may experience symptoms of hypothyroidism, including fatigue, increased sensitivity to cold, constipation, dry skin, puffy face, hair loss, slow heart rate, depression, swelling of the thyroid gland and/or unexplained weight gain or difficulty losing weight.“There is reasonable risk of serious injury in newborn infants or pregnant women with hypothyroidism including early miscarriage, fetal hyperthyroidism, and/or impairments to fetal neural and skeletal development,” wrote Acella. “In elderly patients and patients with underlying cardiac disease toxic cardiac manifestations of hyperthyroidism may occur, such as cardiac pain, palpitations or cardiac arrhythmia.”So far, Acella says it has received four reports of "adverse events" for these lot numbers, possibly related to the recall.The products subject to recall are packed in 100-count bottles. Their lot numbers are M327E19-1 and M328F19-3. And their expiration dates are Oct. 2020 and November 2020.The products were distributed nationwide to Acella’s direct accounts, including wholesalers, pharmacies, and health care offices.“Acella is proactively notifying its wholesalers by email and phone to discontinue distribution of the two above referenced lots being recalled and is arranging for return of all recalled products,” wrote the company.Anyone who is currently taking NP Thyroid from the lots being recalled should not discontinue use without contacting their health care provider for further guidance and/or a replacement prescription, according to Acella.Anyone with questions about the recall can email Acella at recall@acellapharma.com or contact a representative at 1-888-280-2044.Click here for more information. 2272

来源：资阳报